Request Study Information

After you submit your request, a staff member will contact you.There’s no obligation and our team is here to help you decide on a study that’s best for you.

Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults with Elevated Lipoprotein(a) who have Established Atherosclerotic Cardiovascular Disease or Are at Risk for a First Cardiovascular Event – ACCLAIM-Lp(a).

The main purpose of this study is to learn more about lepodisiran which is an experimental treatment for elevated lipoprotein (a) (Lp[a]); which is an increase in a type of fat in your blood that is not good for your health. 

The study aims to learn: 

  • Whether lepodisiran can reduce problems like heart attack or stroke in adults with elevated lipoprotein (a).  
  • Whether it works better than a placebo (a placebo is an inactive or “pretend” drug that looks like the study drug). 
  • What are the possible side effects

Enter Your Information

(All fields are required)

Study Request Form (specific)

Name(Required)
Date of Birth(Required)
Race(Required)
Select one or more options that best describe you. This information can help ensure that all populations are represented in research.

By entering your email address and/or phone number on this form, you represent that you are at least 18 years of age and consent to receiving communications (e.g., call, SMS, text, and/or email) from ECIR and/or the research site(s) involved with the clinical trials that appear on this website. Messaging frequency varies. Message and data rates may apply. You may reply with STOP to a text message. For any help regarding messaging, please email us at [email protected]. For full details, refer to ECIR’s privacy policy and website terms of use. Submissions on this website are not monitored 24/7. Do NOT submit personal health or medical information on this form. If you are enrolled in a trial and have questions, please call your research site.